Fiche société
Cognition Therapeutics
Traitements, essais et publications liés.
Traitements3programmes
Essais2liés
Publications3liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CT1812This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers. | Alzheimer | Phase 2 | À vérifier | United States | À vérifier |
| CT1812This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers. | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| CT1812This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers. | Alzheimer | Phase 2 | À vérifier | United States | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| CT1812 | Alzheimer | Phase 2 | NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| CT1812 | Alzheimer | Phase 1 | NCT05248672 | Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers | COMPLETED |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| CT1812 | Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB). | Alzheimer's & dementia : the journal of the Alzheimer's Association | ||
| CT1812 | Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease. | Journal of Alzheimer's disease : JAD | ||
| CT1812 | Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease. | Alzheimer's research & therapy |